Biogen’s cinpanemab was abandoned in 2021 after it failed a phase 2 study, while Roche/Prothena’s prasinezumab flunked one phase 2 trial, but is still in the phase 2b PADOVA trial in early ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...